Ormeloxifene efficiently inhibits ovarian cancer growth

Area of Science:

• Oncology
• Pharmacology
• Drug Repurposing

Background:

• Ovarian cancer remains a major cause of cancer-related mortality in women.
• There is a critical need for novel anticancer agents effective against chemo-resistant ovarian cancer cells.
• Drug repurposing offers an accelerated pathway for developing new cancer therapies.

Purpose of the Study:

• To investigate the therapeutic potential of ormeloxifene (ORM), a Selective Estrogen Receptor Modulator (SERM), in inhibiting ovarian cancer growth.
• To evaluate ORM's efficacy against both sensitive and chemo-resistant ovarian cancer cell lines.
• To explore the molecular mechanisms underlying ORM's anti-cancer effects.

Main Methods:

• In vitro studies using ovarian cancer cell lines, including cisplatin-resistant variants.
• Analysis of cell viability, apoptosis, and key protein phosphorylation (Akt, p53).
• Assessment of cell cycle regulatory proteins (p27, cyclin E, cyclin D1, CDK2) expression and localization.
• Pre-clinical in vivo studies using xenograft mouse models to evaluate tumorigenesis and metastasis.

Main Results:

• ORM treatment significantly inhibited ovarian cancer cell proliferation and induced apoptosis.
• ORM demonstrated efficacy against cisplatin-resistant ovarian cancer cells.
• ORM modulated key signaling pathways, including decreasing Akt phosphorylation and increasing p53 phosphorylation.
• ORM treatment reduced tumor growth and metastasis in pre-clinical mouse models.

Conclusions:

• Ormeloxifene (ORM) exhibits significant anti-cancer activity against ovarian cancer, including chemo-resistant types.
• ORM's established safety profile in human use makes it a promising candidate for ovarian cancer treatment.
• ORM warrants further clinical investigation for its potential in treating ovarian cancer.